Literature DB >> 25543000

A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma.

Hidetaka Akita1, Ryohei Ishiba2, Ryohei Togashi2, Kota Tange3, Yuta Nakai3, Hiroto Hatakeyama2, Hideyoshi Harashima4.   

Abstract

A renal cell carcinoma (RCC) is one of the refractory tumors, since it readily acquires resistance against chemotherapy. Thus, alternative therapeutic approaches such as obstructing the neovasculature are needed. We previously reported on the development of a plasmid DNA (pDNA)-encapsulating liposomal nanoparticle (LNP) as a hepatic gene delivery system that is applicable to systemic administration. The key molecular component is a SS-cleavable and pH-activated lipid-like material (ssPalm) that mounts dual sensing motifs (ternary amines and disulfide bonding) that are responsive to the intracellular environment. The main purpose of the present study was to expand its application to a tumor-targeting gene delivery system in mice bearing tumors established from a RCC (OS-RC-2). When the modification of the surface of the particle is optimized for the polyethyleneglycol (PEG), stability in the blood circulation is improved, and consequently tumor-selective gene expression can be achieved. Furthermore, gene expression in the tumor was increased slightly when the hydrophobic scaffold of the ssPalm was replaced from the conventionally used myristic acid (ssPalmM) to α-tocopherol succinate (ssPalmE). Moreover, tumor growth was significantly suppressed when the completely CpG-free pDNA encoding the solute form of VEGFR (fms-like tyrosine kinase-1: sFlt-1) was used, especially when it was delivered by the LNP formed with ssPalmE (LNP(ssPalmE)). Thus, the PEG-modified LNP(ssPalmE) is a promising gene carrier for the cancer gene therapy of RCC.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Cancer; Gene delivery; Renal carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25543000     DOI: 10.1016/j.jconrel.2014.12.029

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

Review 1.  Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.

Authors:  Sue Hyun Lee; Jung Bok Lee; Min Soo Bae; Daniel A Balikov; Amy Hwang; Timothy C Boire; Il Keun Kwon; Hak-Joon Sung; Jae Won Yang
Journal:  Adv Healthc Mater       Date:  2015-06-29       Impact factor: 9.933

2.  Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition.

Authors:  Kai Shi; Yi Zhao; Lei Miao; Andrew Satterlee; Matthew Haynes; Cong Luo; Sara Musetti; Leaf Huang
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

Review 3.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

Review 4.  Gene delivery nanoparticles to modulate angiogenesis.

Authors:  Jayoung Kim; Adam C Mirando; Aleksander S Popel; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2016-11-30       Impact factor: 15.470

Review 5.  Drug Delivery Innovations for Enhancing the Anticancer Potential of Vitamin E Isoforms and Their Derivatives.

Authors:  Christiana M Neophytou; Andreas I Constantinou
Journal:  Biomed Res Int       Date:  2015-06-07       Impact factor: 3.411

Review 6.  Production and clinical development of nanoparticles for gene delivery.

Authors:  Jie Chen; Zhaopei Guo; Huayu Tian; Xuesi Chen
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-06       Impact factor: 6.698

Review 7.  Lipid nanoparticle technology for therapeutic gene regulation in the liver.

Authors:  Dominik Witzigmann; Jayesh A Kulkarni; Jerry Leung; Sam Chen; Pieter R Cullis; Roy van der Meel
Journal:  Adv Drug Deliv Rev       Date:  2020-07-02       Impact factor: 15.470

Review 8.  Non-viral COVID-19 vaccine delivery systems.

Authors:  Kyung Soo Park; Xiaoqi Sun; Marisa E Aikins; James J Moon
Journal:  Adv Drug Deliv Rev       Date:  2020-12-17       Impact factor: 17.873

9.  Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex.

Authors:  Zhi-Yao He; Feng Deng; Xia-Wei Wei; Cui-Cui Ma; Min Luo; Ping Zhang; Ya-Xiong Sang; Xiao Liang; Li Liu; Han-Xiao Qin; Ya-Li Shen; Ting Liu; Yan-Tong Liu; Wei Wang; Yan-Jun Wen; Xia Zhao; Xiao-Ning Zhang; Zhi-Yong Qian; Yu-Quan Wei
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

Review 10.  Recent advances in siRNA delivery mediated by lipid-based nanoparticles.

Authors:  Sei Yonezawa; Hiroyuki Koide; Tomohiro Asai
Journal:  Adv Drug Deliv Rev       Date:  2020-08-06       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.